Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-201 and Infliximab in Healthy Participants
NCT07776782Phase 1Recruiting
- Start
- Jul 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MT-201. Primary endpoint: Number of Participants with non-SAEs and SAES at 8 weeks. Started Jul 2026; status: recruiting.
02
Drugs
MT-201
Beyond the preview
Go deeper on NCT07776782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07776782.